TY - CHAP M1 - Book, Section TI - Anal Cancer A1 - Holliday, Emma A1 - Morris, Van A1 - Messick, Craig A. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSDespite the introduction of a preventive human papillomavirus vaccine, both the incidence of anal cancer and the anal cancer–specific mortality rate continue to rise in the United States.Concurrent chemoradiation remains the standard of care for curative-intent therapy for patients with newly diagnosed, locoregional anal cancer.To date, there are no data to support benefit with chemotherapy before or after chemoradiation for patients with locoregional anal cancer.Salvage surgery with abdominoperineal resection remains the standard of care for patients with nonmetastatic, locoregional anal cancer that recurs after chemoradiation.Combination chemotherapy is the current treatment recommendation in the frontline setting for patients with inoperable, metastatic anal cancer.Immune checkpoint blockade therapies, either as monotherapy or as a clinical trial option, should be considered for patients with treatment-refractory anal cancer. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1190835971 ER -